Cingulate completes pre-NDA meeting with FDA on NDA for CTx-1301
Cingulate (CING) announced that it held a Pre-NDA meeting with the U.S. Food and Drug Administration, FDA, yesterday to discuss the submission ...
Tovecimig (CTX-009) Meets Primary Endpoint in the Ongoing Randomized Phase 2/3 Study in Patients with Biliary Tract Cancer
Tovecimig (a DLL4 x VEGF-A bispecific antibody) in combination with paclitaxel achieved a 17.1% overall response rate (ORR), including one ...